In Brief Gelegen et al. show that the lateral habenula is a key hub whose excitation is permissive for the sedative effects of propofol. When the output from the lateral habenula is blocked, propofol's sedative effects are greatly diminished, and NREM sleep is highly fragmented.
SUMMARY
The lateral habenula has been widely studied for its contribution in generating reward-related behaviors [1, 2] . We have found that this nucleus plays an unexpected role in the sedative actions of the general anesthetic propofol. The lateral habenula is a glutamatergic, excitatory hub that projects to multiple targets throughout the brain, including GABAergic and aminergic nuclei that control arousal [3] [4] [5] . When glutamate release from the lateral habenula in mice was genetically blocked, the ability of propofol to induce sedation was greatly diminished. In addition to this reduced sensitivity to propofol, blocking output from the lateral habenula caused natural non-rapid eye movement (NREM) sleep to become highly fragmented, especially during the rest (''lights on'') period. This fragmentation was largely reversed by the dual orexinergic antagonist almorexant. We conclude that the glutamatergic output from the lateral habenula is permissive for the sedative actions of propofol and is also necessary for the consolidation of natural sleep.
RESULTS AND DISCUSSION
Propofol is the most widely used intravenous (i.v.) general anesthetic, and its molecular target, the GABA A receptor, has long been known [6] [7] [8] ; however, the neuronal circuits that mediate its sedative and anesthetic effects are a mystery [9] . In humans and rodents, the effects of propofol on the electroencephalogram (EEG) have been thoroughly characterized, with the key feature being the increased coherence of thalamocortical oscillations [10] [11] [12] , with changes in the higher-order thalamic nuclei correlating with loss of consciousness [10, 13] . But which neuronal circuits trigger these changes? Because low-frequency thalamocortical oscillations also increase during NREM sleep, an obvious possibility was that propofol was directly affecting hypothalamic nuclei involved in sleep and arousal [14, 15] . The arousal-promoting histaminergic neurons in the hypothalamic tuberomammillary nucleus have since been shown to be a plausible target for GABAergic sedatives, such as zolpidem [16, 17] , and modulation of hypothalamic pathways has also been implicated in the actions of volatile general anesthetics [18, 19] .
During the sedation produced by systemically administered GABAergic general anesthetics, as well as by the a2 adrenergic agonist dexmedetomidine, cFOS expression increases in sleeppromoting neurons and decreases in arousal-promoting neurons [14, 20, 21] . A comprehensive study [22] surveyed cFOS expression throughout the brain in response to a variety of sedatives and compared these changes with those observed during the natural sleep-wake cycle. One remarkable observation in this and a subsequent report [23] was that sedative agents induced marked cFOS expression in the lateral habenula (LHb). Because cFOS expression marks neuronal excitation, we have investigated whether the sedative actions of propofol require neurons of the LHb to be excited.
Propofol Selectively Induces cFOS Expression in the LHb
We first confirmed that sedative doses of propofol do indeed increase cFOS expression in the LHb above those induced by saline injection (previous studies had used a variety of GABAergic drugs but propofol has not itself been investigated in this regard). Basal cFOS expression was found throughout the brain, including in the neocortex and the midline thalamic nuclei ( Figure 1A ; left panels). Figure 1A (right panels) also shows that a sedative dose of propofol (212 ± 22 s of loss of righting reflex; mean ± SD; n = 6) caused a marked expression of cFOS in the LHb above the levels seen with a saline injection. We explored the possibility that propofol might directly excite LHb neurons but found that in acute slices from LHb-GFP mice, 1.5 mM propofol, an appropriate concentration for loss of righting reflex (LORR) [24] , had no effect on the resting membrane potential (V m = À46.2 ± 2.1 mV for control, V m = À46.6 ± 2.4 mV with propofol; n = 15, p = 0.59; paired two-tailed t test), showing that the excitation must be by disinhibition elsewhere in the circuitry. To investigate whether or not this propofolinduced excitation (disinhibition) of the LHb was a cause or a consequence of sedation, we sought to block the glutamatergic output of the LHb to see whether this affected the sedative actions of the drug.
Excitatory Output from the LHb Can Be Selectively Blocked Using Grm2-Cre Mice and Tetanus Toxin Light Chain To selectively manipulate the LHb, we identified the metabotropic glutamate receptor 2-Cre recombinase (Grm2-Cre) mouse line, which has Cre recombinase expression in the LHb, but not the medial habenula (MHb) (see STAR Methods for a description of this mouse line). We then silenced the LHb with an adeno-associated virus (AAV) that expressed a Cre-dependent tetanus-toxin-light-chain (TeLC) transgene [25] . This toxin cleaves the vesicle-associated membrane protein synaptobrevin-2, which plays a key role in neurotransmitter release [26] . We injected AAV-flex-GFP-TeLC bilaterally into the LHb of Grm2-Cre mice to selectively block neurotransmission from these neurons (LHb-TeLC mice) ( Figures 1B, S1 , S2A, and S2B). Control mice were generated by bilaterally injecting AAV-flex-GFP into Grm2-Cre mice (LHb-GFP mice). LHb-TeLC mice had no overt neurological symptoms, and their weights (30.2 ± 4.3; mean ± SD) did not differ (p = 0.12; unpaired two-tailed t test) from LHb-GFP controls (33.2 ± 4.8; mean ± SD). The Cre-dependent transgene expression in cell bodies was confined to the LHb (Figures 1B and S1 ). There was no cell body expression in the MHb, or in midline thalamic structures. GFP-TeLC transgene expression was seen in Grm2-Cre neurons throughout the LHb. To further visualize axons from these neurons, we also injected AAV-flex-ChR2-EYFP (LHb-ChR2 mice) ( Figures S2C and S2D ). We traced the projections from these neurons to their targets (Figures S2 and S3). Many axonal fibers in the LHb-TeLC and LHb-ChR2 mice were strongly positive, including the fasciculus retroflexus, the main fiber bundle from the LHb ( Figures S2 and  S3 ). In addition to the anticipated projections to the ventral tegmental area (VTA), substantia nigra, and dorsal raphe areas ( Figure S2 ), there were also unexpected GFP-TeLC-and ChR2-EYFP-positive fibers outlining the midline thalamic nuclei (including the central lateral, the central medial, the intermediodorsal, and the reunions nuclei), in the lateral hypothalamus, in the preoptic hypothalamus, especially the median preoptic nucleus, the septal hippocampal nucleus, the dorsal-lateral caudate-putamen ( Figures S2 and S3 ), and in the prefrontal cortex ( Figure S3 ), as well as in the mammillary area ( Figure S2 ). Thus Grm2-Cre neurons in the LHb project more widely than anticipated, and their firing is likely to influence many brain regions.
To determine the transmitter phenotype, we patched EYFPpositive LHb neurons in acute slices from LHb-ChR mice, extracted their mRNA, and did real-time PCR assays (Figure S3A ). EYFP-positive (Grm2-Cre) LHb neurons, and also non-EYFP-expressing LHb neurons, expressed the Vglut2 gene, which encodes a glutamate vesicular transporter, but many cells also expressed low levels of the GABAergic Gad1(Gad67) gene ( Figure S3 ). In a parallel assay to confirm specificity of the PCRs, neocortical pyramidal neurons randomly chosen and patched from the same slices did not contain Vglut2 or Gad1 transcripts ( Figure S3 ). To confirm that Grm2-Cre LHb neurons used glutamate as their predominant neurotransmitter, and that GFP-TeLC blocked their transmitter release, we injected either AAV-flex-ChR2-EYFP alone into the LHb of Grm2-Cre mice (LHb-ChR2 mice) or co-injected AAV-flex-ChR2-EYFP and AAV-flex-GFP-TeLC (LHb-ChR2/LHb-TeLC mice). We then made acute brain slices from several example projection regions, containing either prefrontal cortex (PFC) or dorsal caudate-putamen, from both groups of mice. In slices from these areas of LHb-ChR2 mouse brains, light pulses evoked excitatory postsynaptic (A) Propofol-induced LORR at 7 mg/kg (i.v.) was blocked in LHb-TeLC mice (unpaired two-tail t test; p = 1.1 3 10 À7 , t = 6.69, df = 34, n = 14 LHb-GFP mice and 22 LHb-TeLC mice). (B) Propofol caused a nearly 3-fold rightward shift in the quantal dose-response curve (p = 0.009, unpaired two-tailed t test, t = 70, df = 1). (C) Propofol-induced (7 mg/kg) sedation in control LHb-GFP mice (two-way ANOVA; p < 1.0 3 10 À4 , F 17,414 = 4.80, n = 11 saline and 14 propofol). (D) Lack of propofol-induced (7 mg/kg) sedation in LHb-TeLC mice (two-way ANOVA; p = 0.26, F 17,731 = 1.19, n = 21 saline and 23 propofol). (E) Propofol-induced (7 mg/kg) changes in the global EEG wavelet power spectra from control LHb-GFP mice (p = 0.02, paired two-tailed t test, n = 7 saline and 7 propofol), (F) Propofol (7 mg/kg) induced much smaller changes in the global EEG wavelet power spectra in LHb-TeLC mice (p = 0.03, paired two-tailed t test, n = 7 saline and 7 propofol). Figure S3H ), presumably because the neurons that gave rise to these axons had not been co-transduced with the two AAVs. But overall, the large decrease in evoked EPSCs in LHb-ChR2/LHb-TeLC confirmed that TeLC expression in Grm2-Cre neurons in the LHb blocks their neurotransmitter release.
Blocking Output from the LHb Greatly Diminishes the Sedative Effects of Propofol
We next investigated the effects of bolus doses of propofol sufficient to induce sedation and LORR, but not deep anesthesia. At a dose of 7 mg/kg (i.v.) LHb-GFP mice had LORR that lasted on average for 90 ± 16 s (mean ± SEM; n = 14) ( Figure 2A ). LHb-TeLC mice by contrast were virtually unresponsive to this dose of propofol: they had only a short (5 ± 1 s; n = 22) LORR ( Figure 2A ). The quantal dose-response curve for propofol ( Figure 2B ) was shifted to the right by about a factor of 3. Even after they recovered from LORR, the locomotion of the LHb-GFP mice was impaired (p < 10 À4 ) for several minutes following propofol injection compared with saline injected controls ( Figure 2C ), whereas the locomotion of the LHb-TeLC mice was unaffected (p > 0.3) (Figure 2D ). These differences in propofol sensitivity were reflected in the EEG: in LHb-GFP control mice, a propofol injection compared with saline elicited a nearly 3-fold increase in power, with increases in both delta frequency power, as well as producing an increase in the power of a broad range of frequencies >10 Hz extending to the gamma range, 30-40 Hz (Figure 2E ), as we found in rats [10] . By contrast, in LHb-TeLC mice, propofol injection, when compared with a saline injection, produced much smaller ($60% increase) changes in delta frequency power, as well as at higher frequencies ( Figure 2F ), although the overall increase in power was still significant (p = 0.034). Wavelet spectra as a function of time (Figures 2G and 2H) show that these increases in EEG power occur almost immediately following propofol injection (at 50 s).
Stimulating Output from the LHb Reduces Motor Activity
Acute electrical stimulation of the LHb in cats strongly induces NREM sleep [27] , yet on the other hand, lesioning the LHb Expression of the receptor, detected with mCherry immunocytochemistry, was restricted to cells in the LHb. DG, dentate granule cells; 3V, third ventricle. (B) Bath application of 5 mM CNO in a brain slice preparation led to an increase in resting membrane potential of 9.0 ± 3.1 mV from À59.2 ± 3.5 to À50.2 ± 3.5 mV (paired two-tailed t test; n = 8 neurons, 3 mice; p = 0.023, t = 2.88, df = 7). Resting membrane potential was calculated as an average voltage (sampled every 200 ms) between 1 and 3 min immediately before bath application of CNO and at the peak of the effect 5-10 min after drug administration. (C) Locomotor speed was recorded in an open field for 20 min, 20 min after CNO (5 mg/kg, i.p.) injection or saline injection, and the speed was reduced approximately 2-fold (paired two-tailed t test; n = 10 mice; p = 2.26 3 10 À4 , t = 5.91, df = 9) following CNO injection. (B and C) Symbols are mean ± SEM. in rats slightly decreases the amount of REM sleep and theta power in the EEG without affecting NREM sleep [28] . There are, however, many subtypes of glutamatergic projection neuron in the LHb [29, 30] ; for example, only subsets of LHb neurons convey error prediction [1] . Similarly, it is feasible that only certain neuronal subtypes in the LHb are responding to propofol. To corroborate our results obtained with propofol, we tested whether pharmacogenetic excitation of Grm2-Cre neurons in the LHb mimicked the effects of propofol. We bilaterally injected AAV-flex-hM3D q -mCHERRY into the LHb of Grm2-Cre mice (LHb-hM3D q mice, Figure 3A) ; hM3D q receptor expression was confined to the LHb ( Figure 3A) . The metabotropic hM3D q receptor, when activated by its ligand clozapine-N-oxide (CNO), is excitatory [31] . In acute slices containing LHb, we patch-clamped neurons expressing the hM3D q receptor (identified by mCHERRY fluorescence). CNO application caused a gradual depolarization (9.0 ± 3.1 mV; n = 8) (Figure 3B) , often resulting in a train of action potentials. Systemically injecting LHb-hM3D q mice with CNO decreased their movement $2-fold (p = 2.3 3 10 À4 ; n = 10) ( Figure 3C ) compared with saline injections. During the time that this reduction in mobility was recorded (20-40 min after CNO injection), there was no significant increase in the percentage of time scored as NREM sleep (p = 0.52). Because CNO is metabolized to clozapine, which also acts as a ligand at hM3D q receptors [32] , we checked that CNO (5 mg/kg i.p.) did not significantly affect motor activity in LHb-mCherry mice compared to saline injection (p = 0.44, two-tailed paired t test n = 5). REM was identical between LHb-GFP and LHb-TeLC mice (two-way ANOVA; wake: p = 0.96, F 23,456 = 0.53; NREM: p = 0.96, F 23,456 = 0.53; REM: p = 0.84, F 23,456 = 0.71. (B) Four left-hand panels: the number of episodes of wake, NREM, and sleep (defined as a consolidated period of NREM and REM) was larger in LHb-TeLC mice (n = 9) than Lhb-GFP mice (n = 13), although their durations were generally proportionately shorter (unpaired two-tail t tests). These changes were greater during ''lights ON'' (wake episodes: p = 6.7 3 10 À9 , t = 9.56; wake duration: p = 9.3 3 10 À5 , t = 4.87; NREM episodes: p = 2.2 3 10 À6 , t = 6.54; NREM duration: p = 1.7 3 10 À6 , t = 6.66; sleep episodes: p = 3.5 3 10 À8 , t = 8.63; sleep duration: p = 1.8 3 10 À5 , t = 5.58; df = 20) compared with ''lights OFF'' (wake episodes: p = 1.7 3 10 À3 , t = 3.63; wake duration: p = 0.18, t = 1.38; NREM episodes: p = 6.4 3 10 À3 , t = 3.05; NREM duration: p = 3.9 3 10 À4 , t = 4.26; sleep episodes: p = 3.6 3 10 À3 , t = 3.29; sleep duration: p = 7.8 3 10 À3 , t = 2.95; df = 20). There were no changes (unpaired two-tail t test) in either episode number or duration for REM for either ''lights ON'' (p = 0.26, t = 1.17 and p = 0.38, t = 0.09, df = 20) or ''lights OFF'' (p = 0.91, t = 0.11 and p = 0.38, t = 0.90, df = 20). Two right-hand panels: cumulative distributions for wake and NREM bout durations during ''lights ON.'' (C) Blocking the output of LHb Grm2-Cre neurons with TeLC greatly increased wake-NREM and NREM-wake transitions (red arrows) during both ''lights ON'' (p = 7.0 3 10 À6 , t = 5.92 and p = 1.4 3 10 À4 , t = 4.62, respectively; df = 21) and ''lights OFF'' (p = 0.01, t = 2.58 and p = 8.0 3 10 À3 , t = 2.92, respectively, df = 21) but also caused an increase in REM-wake transitions during ''lights ON'' (p = 7.0 3 10 À3 , t = 2.98, df = 21, red arrow). The values by the arrows are average transitions per hour. (D-F) The orexin receptor antagonist, almorexant, largely reversed the sleep fragmentation that was observed in the LHb-TeLC mice. During the 12 hr after i.p. injection of almorexant (30 mg/kg) into LHb-TeLC mice, (D) the percentage of time in the wake state was reduced (repeated-measures ANOVA, F treatment (1,96) = 8.27, p = 0.005), (E) the percentage of time in the NREM state was increased (repeated-measures ANOVA, F treatment (1,96) = 9.45, p = 0.003), but (F) there was no change in the time spent in REM. (G) The number of wake (p = 1.4 3 10 À4 ), NREM (p = 0.059), and sleep (consolidated NREM + REM) episodes (p = 0.002) were reduced, with no change in the number of REM episodes. (H) Moreover, the average durations of wake, NREM (p = 0.035), and sleep (p = 2.1 3 10 À4 ) increased, with no change in the average duration of REM episodes (n = 4 vehicle and n = 6 almorexant). Where error bars are shown they represent SEM. See also Figure S4 .
Blocking Output from the LHb Causes Marked Fragmentation of NREM Sleep
Because manipulations of anesthetic targets often affect sleep architecture [16, 33] , we next explored whether chronically silencing LHb Grm2-Cre neurons affected natural sleep over 24 hr (Figure 4) . LHb-TeLC mice did not differ from LHb-GFP mice in their overall time spent in wake, NREM, or REM sleep (p > 0.8; n = 9-11); both groups of mice had a typical 24-hr activity profile, with less wakefulness during ''lights ON'' ( Figure 4A ), although the delta power during NREM in LHb-TeLC mice was slightly lower than that in LHb-GFP mice (p = 0.02) ( Figure S4A ). However, there was a large difference in sleep consolidation (Figures 4B, S4B, and S4C ). The number of wake and NREM episodes was substantially higher in LHb-TeLC mice compared with LHb-GFP mice, particularly during ''lights ON,'' but the durations of these states were proportionately reduced ( Figures  4B, S4B, and S4C ). Taking this analysis further, the duration of entire sleep episodes (defined as REM plus NREM in a continuous block) decreased strongly, particularly during ''lights ON,'' but their number increased proportionately ( Figures 4B,  S4B , and S4C). REM sleep frequency and duration was unchanged in LHb-TeLC mice compared with LHb-GFP mice, but in LHb-TeLC mice, there was a high number of REM-wake transitions that were not apparent in control mice ( Figure 4C) . Thus, LHb-TeLC mice had a severely fragmented pattern of natural NREM sleep.
Why should the sleep fragmentation phenotype be greatest during the ''lights-ON'' period? The LHb receives afferents from both the suprachiasmatic nucleus that houses the master circadian clock and the pineal gland [3] . LHb neurons fire when light activates the retina [34] but also maintain an intrinsic circadian rhythmicity in action potential firing in acute brain slices [34, 35] . Thus, LHb activity could help maintain sleep during daylight, when mice are resting more. Intriguingly, we found that the sleep fragmentation phenotype of LHb-TeLC mice was largely reversed by systemic administration of the dual orexin receptor antagonist almorexant ( Figures 4D-4H ). Almorexant caused an overall reduction in waking that lasted several hours ( Figure 4D ) and a corresponding increase in NREM sleep (Figure 4E) , with no significant changes in REM ( Figure 4F) . These changes were due to the number of wake and sleep (consolidated NREM + REM) episodes decreasing, but the durations of NREM and sleep increasing ( Figures 4G and 4H) . These results suggest that excessive activation of the orexin system contributes to the sleep-wake fragmentation in LHb-TeLC mice. This is perhaps because of failure to excite GABA neurons that inhibit orexin neurons and is consistent with the presence of LHb Grm2-Cre axons in the lateral hypothalamic area ( Figure S2 ). This explanation is consistent with the observation that in mice that overexpress orexin [36] , sleep is fragmented with significantly more wake and NREM episodes, but with reduced durations, particularly during ''lights ON.''
What Role Does the Propofol-Induced Excitation of the LHb Play in Sedation?
It has been hypothesized that the LHb has diverse roles, all united by a common theme of motor suppression [3] . The LHb is a glutamatergic hub [3, 5] that receives input from diverse forebrain regions (e.g., the PFC, basal ganglia, and preoptic and lateral hypothalamus [3, 5] ) and projects to GABAergic neurons of the rostromedial tegmental nucleus [37] , a nucleus at the caudal end of the VTA. Trans-synaptic retrograde tracing has shown that GABAergic neurons throughout the VTA receive a disproportionately large input from the LHb [38] , and this could provide a powerful inhibitory control of motor responses [4] by inhibiting dopamine and serotonin neurons [2, 3] . In keeping with its diverse modulatory roles, dopamine also supports wakefulness [39] . Selectively activating dopamine neurons optogenetically in a downstream target of the LHb, the VTA, induces both consolidated wakefulness [39] and also prompt wakening from general anesthesia [40] .
The above findings are certainly consistent with our observation that selective excitation of the LHb reduces motor activity. Because blocking LHb glutamatergic output prevents propofol-induced loss of muscle tone (LORR) and also reduces the propofol-induced enhancement in EEG power, this implies the LHb must be able to modulate the thalamocortical coherence that is a hallmark of propofol's sedative and anesthetic effects. It is most commonly assumed that sedation is a consequence of anesthetics activating, or potentiating, inhibitory circuits. Our findings, however, show that the activation of an excitatory pathway is mechanistically essential for propofol-induced sedation.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: pronuclear injection of a BAC transgene containing a Cre recombinase reading frame inserted into the metabotropic glutamate receptor 2 gene [41] . We maintained the line as heterozygotes. Genotyping primers for the Grm2-Cre line were Grm2(34611)F (5 0 -GGCAGCCACTCTTTGGTTCTACTC-3 0 ) and CreGS-R1 (5 0 -CGGCAAACGGACAGAAGCATT-3 0 ); a 375 bp product indicated the transgene (protocol and primer sequences recommended by the Mouse Mutant Resource Centre, https://www.mmrrc.org/). Male mice (3 -5 months old) were kept on a 12:12 light:dark cycle, 22 ± 1 C, 50% relative humidity, at a maximum of four animals per cage, with free access to food and water. Following surgery, mice were kept singly housed. Behavioral experiments, except where specified otherwise, were performed during the ''Lights OFF'' period.
METHOD DETAILS

AAV transgenes
The AAV-flex-GFP-TeLC transgene plasmid was described previously [25] . The GFP protein is fused to the N terminus of TeLC. The AAV-flex-EGFP transgene was Addgene plasmid 28304 (gift from Edward Boyden, MIT, Cambridge, USA). The AAV-flex-ChR2(H134R)-EYFP transgene was a gift from Karl Deisseroth (Addgene plasmid 20298). This expresses the humanized ChR2 gene with histidine 134 changed to arginine, to make larger currents; EYFP is fused to the C terminus of ChR2, which also makes it a good substrate for axonal transport. The AAV-flex-hM3D q -mCHERRY transgene was a gift from Bryan L. Roth (Addgene plasmid 44361) [42] . The mCherry protein is fused to the C terminus of hM3Dq.
Generation of recombinant AAV particles
All AAV transgenes were packaged into AAV capsids (mixed serotype 1 & 2, 1:1 ratio of AAV1 and AAV2 capsid proteins with AAV2 ITRs) [43] . HEK293 cells (obtained from the European Collection of Cell Cultures (ECACC) via Sigma-Aldrich) were co-transfected, using the calcium phosphate method, with AAV transgene plasmid, the adenovirus helper plasmid pFD6, and the AAV helper plasmids pH21 (AAV1), and pRVI (AAV2) [43] . 60-65 hours after transfection, cells were washed in 1 x PBS, and pelleted; pellets were resuspended in 150 mM NaCl, 20 mM Tris pH 8.0. Then sodium deoxycholate (Sigma #D5670) and benzonase endonuclease (Sigma #E1014) were added and incubated at 37 C for 1 hr. After incubating, cell debris were removed by centrifugation and AAV particles were purified from the supernatant by passing over a heparin column (1 mL HiTrap Heparin columns, Sigma #5-4836), which binds the AAV particles. The column was pre-equilibrated with 10 mL 150 mM NaCl, 20 mM Tris pH 8.0. Then the supernatant was loaded onto the column at a flow rate of 200 ml/min; the column was washed with 20 mL 100 mM NaCl, 20 mM Tris pH 8.0 and virus was eluted off the column as follows: 1 mL 200 mM NaCl, 20 mM Tris pH 8.0 (discarded), 1 mL 300 mM NaCl, 20 mM Tris pH 8.0 (discarded), 1.5 mL 400 mM NaCl, 20 mM Tris pH 8.0 (collected), 3 mL 450 mM NaCl, 20 mM Tris pH 8.0 (collected), 1.5 mL 500 mM NaCl, 20 mM Tris pH 8.0 (collected). After purification, AAV particles were concentrated using Amicon Ultra-4 (100000MWCO, #UFC810024, Millipore, Watford, Hertfordshire, UK) at 2000 g for 10 min. The concentrator was twice refilled with 3.5 mL of 0.9% NaCl. Elutions were removed to a sterile tube, and 250 mL of 0.9% NaCl were added. AAV was aliquoted and stored at -80 C.
Stereotaxic injections of AAV
All the AAV-injection experiments used adult male heterozygote Grm2-Cre mice, 8-12 weeks old. Mice were anesthetized with 2% isoflurane in oxygen by inhalation and mounted into a stereotaxic frame (Angle Two, Leica Microsystems, Milton Keynes, Buckinghamshire, UK). AAV was injected using Hamilton microliter #701 10 mL syringes with a 33-gauge stainless steel needle (Point style 3, length 1.5 cm, Hamilton), back loaded with mineral oil and AAV mixture (1:1 with 20% mannitol) in the tip. For the LHb-ChR2/LHb-TeLC mice, the two AAVs, AAV-flex-ChR2-EYFP and AAV-flex-TeLC-EGFP were mixed 1:1 prior to injection. The coordinates of the (bilateral) injection sites according to the digital atlas of the Leica apparatus were relative to Bregma: AP, À1.70; ML -/+ 0.44; DV was consecutive, starting +2.90 (1/3 volume), +2.85 (1/3 volume), +2.80 (1/3 volume). To make the LHb-ChR2/LHb-TeLC mice, a total volume of 1 mL of AAV was divided into three aliquots for each side of the brain; to generate the LHb-hM3Dq mice, we used a total of 0.6 mL per brain side, again divided into three aliquots for each consecutive injection. Mice that had been injected with AAVs were allowed 1 month to recover in their home cages and for the viral transgenes to adequately express before being fitted with Neurologger 2A devices (see below) and undergoing behavioral experiments.
EEG and EMG recordings and sleep scoring
For non-tethered EMG and EEG recordings, mice were chronically implanted with skull screw electrodes (-1.5 mm Bregma, +1.5 mm midline -first recording electrode; +1.5 mm Bregma, -1.5 mm midline -second recording electrode; -1 mm Lambda, 0 mm midlinereference electrode) to measure cortical EEG. A pair of stainless steel EMG electrodes was implanted in dorsal neck muscle. The electrical signals were recorded on a wireless electronic recording device (Neurologger 2A) as described previously [44, 45] . Four data channels could be recorded at a sampling rate of 200 Hz and waveforms visualized using Spike2 software (Cambridge Electronic Design, Cambridge, UK) or MATLAB (MathWorks, Cambridge, UK). The EEG was high-pass filtered (1 Hz, À3dB) using a digital filter and the EMG was band-pass filtered between 5-48 Hz (À3dB). Power in the delta (0-4 Hz) and theta (6-10 Hz) bands were calculated, together with the RMS value of the EMG signal (averaged over a bin size of 5 s), and these were used to define the
